P5091 (882257-11-6) is a selective inhibitor of the ubiquitin-specific protease USP7 ( IC50=4.2 μM).1,2 Induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance.1?P5091 displays antiangiogenic activity in vivo.2?Cell permeable
P005091 is a selective dual inhibitor of the cancer-related deubiquitylating proteases USP7 and USP47.
P5091 has been used:
- as a ubiquitin specific peptidase 47 (USP47) inhibitor in 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay to evaluate the cellular viability of MCF-10A cells
- as a USP7 inhibitor to study the regulatory role for USP7 on inflammasome activation
- as USP7 inhibitor in drug susceptibility assays to study its effect on bone marrow?resident tumor cells (BMRTCs)/ circulating tumor cells (CTCs)
P5091 plays an important role in ovarian cancer, as it can prevent the growth of cells and can promote necrosis and apoptosis.
1) Chauhan et al. (2012), A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance; Cancer Cell, 22 345
2) Weinstock et al. (2012), Selective dual inhibitors of the cancer-related deubiquitylating proteases USP7 and USP47; ACS Med. Chem. Lett., 3 789
